You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSilodosin
Accession NumberDB06207
TypeSmall Molecule
GroupsApproved
Description

Silodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008.

Structure
Thumb
Synonyms
KAD 3213
KMD 3213
Rapaflo
Urief
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Rapaflocapsule4 mg/1oralActavis Pharma, Inc.2009-03-23Not applicableUs
Rapaflocapsule4 mg/1oralAvera Mc Kennan Hospital2015-05-01Not applicableUs
Rapaflocapsule8 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Rapaflocapsule8 mgoralActavis Specialty Pharmaceuticals Co2011-10-26Not applicableCanada
Rapaflocapsule4 mgoralActavis Specialty Pharmaceuticals Co2011-10-26Not applicableCanada
Rapaflocapsule8 mg/1oralPhysicians Total Care, Inc.2010-09-15Not applicableUs
Rapaflocapsule8 mg/1oralActavis Pharma, Inc.2009-03-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RapilifIpca Urosciences
Silodyx Recordati Industria Chimica e Farmaceutica S.p.A.
UriefWatson Pharmaceuticals Inc.
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICUZ39LUY82
CAS number160970-54-7
WeightAverage: 495.5345
Monoisotopic: 495.234491142
Chemical FormulaC25H32F3N3O4
InChI KeyInChIKey=PNCPYILNMDWPEY-QGZVFWFLSA-N
InChI
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
IUPAC Name
1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
SMILES
C[[email protected]](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolecarboxylic acids and derivatives
Direct ParentIndolecarboxamides and derivatives
Alternative Parents
Substituents
  • Indolecarboxamide derivative
  • Benzamide
  • Dialkylarylamine
  • Phenol ether
  • Benzoyl
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Vinylogous amide
  • 1,3-aminoalcohol
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationTreatment for symptomatic relief of benign prostatic hyperplasia
PharmacodynamicsSilodosin is 583 times more selective for human alpha-1A receptors than alpha-1B receptors. It is also 56 times more selective for human alpha-1A receptors than alpha-1D. Silodosin does not prolong the QT interval.
Mechanism of actionBenign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH.
Related Articles
AbsorptionQuickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose). When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: Cmax = 61.6 ± 27.54 ng/mL; Tmax = 2.6 ± 0.90 hours; AUC (0h-24h) = 373 ng•hr/ml. The AUC of its metabolite, KMD3213G, is four times greater than silodosin.
Volume of distribution

49.5 L

Protein binding97% bound to protein
Metabolism

Extensively metabolized in the liver. The main metabolite is generated via glucuronidation (KMD-3213G) by UDP-2B7. Oxidation by alcohol and aldehyde dehydrogenases produces the second major metabolite, KMD-3293. KMD-3213G accumulates in the plasma as it is very hydrophilic. KMD-3213G is also an active metabolite in which it has 50% of silodosin's inhibitory activity. KMD-3293 is inactive. Cytochrome P450 CYP 3A4 also generates some metabolites.

Route of eliminationFecal (54.9%); Renal (33.5%)
Half lifeSilodosin = 13.3 ± 8.07 hours; KMD-3213G = 24 hours;
Clearance

Plasma clearance = 10 L/h

ToxicityMost common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7383
Caco-2 permeable-0.5847
P-glycoprotein substrateSubstrate0.8467
P-glycoprotein inhibitor INon-inhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.7864
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.8226
CYP450 2D6 substrateNon-substrate0.6362
CYP450 3A4 substrateSubstrate0.6585
CYP450 1A2 substrateNon-inhibitor0.7439
CYP450 2C9 inhibitorNon-inhibitor0.7569
CYP450 2D6 inhibitorNon-inhibitor0.5958
CYP450 2C19 inhibitorNon-inhibitor0.5562
CYP450 3A4 inhibitorInhibitor0.7424
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5723
Ames testNon AMES toxic0.6667
CarcinogenicityNon-carcinogens0.8529
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4845 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Inhibitor0.8366
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral4 mg/1
Capsuleoral4 mg
Capsuleoral8 mg
Capsuleoral8 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5387603 No1998-12-012018-12-01Us
US5403847 No1992-11-132012-11-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 - 109°CFDA label
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0111 mg/mLALOGPS
logP2.96ALOGPS
logP3.05ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.87ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.05 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity128.92 m3·mol-1ChemAxon
Polarizability49.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Yoshida M, Homma Y, Kawabe K: Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007 Dec;16(12):1955-65. [PubMed:18042003 ]
  2. Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41. [PubMed:17603160 ]
External Links
ATC CodesG04CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (846 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Silodosin can be increased when it is combined with Abiraterone.
AlfuzosinAlfuzosin may increase the antihypertensive activities of Silodosin.
AmiodaroneThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.
AmlodipineSilodosin may increase the hypotensive activities of Amlodipine.
AmrinoneSilodosin may increase the hypotensive activities of Amrinone.
AprepitantThe serum concentration of Silodosin can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Silodosin can be increased when it is combined with Atazanavir.
AtorvastatinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.
AzithromycinThe serum concentration of Silodosin can be increased when it is combined with Azithromycin.
BepridilSilodosin may increase the hypotensive activities of Bepridil.
BexaroteneThe serum concentration of Silodosin can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Silodosin can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Silodosin can be decreased when it is combined with Bosentan.
CarvedilolThe serum concentration of Silodosin can be increased when it is combined with Carvedilol.
CeritinibThe serum concentration of Silodosin can be increased when it is combined with Ceritinib.
ClarithromycinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Silodosin can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Silodosin can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Silodosin can be increased when it is combined with Crizotinib.
CyclosporineThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.
DabrafenibThe serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Silodosin can be increased when it is combined with Daclatasvir.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Silodosin.
DarunavirThe serum concentration of Silodosin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.
DipivefrinSilodosin may decrease the vasoconstricting activities of Dipivefrin.
DipyridamoleThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.
DronedaroneThe serum concentration of Silodosin can be increased when it is combined with Dronedarone.
EliglustatThe serum concentration of Silodosin can be increased when it is combined with Eliglustat.
ErythromycinThe serum concentration of Silodosin can be increased when it is combined with Erythromycin.
FelodipineSilodosin may increase the hypotensive activities of Felodipine.
FlibanserinThe serum concentration of Silodosin can be increased when it is combined with Flibanserin.
FluconazoleThe metabolism of Silodosin can be decreased when combined with Fluconazole.
FlunarizineSilodosin may increase the hypotensive activities of Flunarizine.
FosaprepitantThe serum concentration of Silodosin can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Silodosin can be increased when it is combined with Fusidic Acid.
GabapentinSilodosin may increase the hypotensive activities of Gabapentin.
IbrutinibThe serum concentration of Silodosin can be increased when it is combined with Ibrutinib.
IdelalisibThe serum concentration of Silodosin can be increased when it is combined with Idelalisib.
IndinavirThe serum concentration of Silodosin can be increased when it is combined with Indinavir.
IsradipineSilodosin may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Silodosin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Silodosin can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Silodosin can be increased when it is combined with Ketoconazole.
LamotrigineSilodosin may increase the hypotensive activities of Lamotrigine.
LapatinibThe serum concentration of Silodosin can be increased when it is combined with Lapatinib.
LercanidipineSilodosin may increase the hypotensive activities of Lercanidipine.
LomitapideThe serum concentration of Silodosin can be increased when it is combined with Lomitapide.
LuliconazoleThe serum concentration of Silodosin can be increased when it is combined with Luliconazole.
Magnesium SulfateSilodosin may increase the hypotensive activities of Magnesium Sulfate.
MefloquineThe serum concentration of Silodosin can be increased when it is combined with Mefloquine.
MidodrineSilodosin may decrease the vasoconstricting activities of Midodrine.
MifepristoneThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.
MirabegronThe serum concentration of Silodosin can be increased when it is combined with Mirabegron.
MitotaneThe serum concentration of Silodosin can be decreased when it is combined with Mitotane.
NadololNadolol may increase the orthostatic hypotensive activities of Silodosin.
NefazodoneThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Silodosin can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Silodosin can be increased when it is combined with Netupitant.
NicardipineThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.
NilotinibThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.
NimodipineSilodosin may increase the hypotensive activities of Nimodipine.
NisoldipineSilodosin may increase the hypotensive activities of Nisoldipine.
NitrendipineSilodosin may increase the hypotensive activities of Nitrendipine.
PalbociclibThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.
PerhexilineSilodosin may increase the hypotensive activities of Perhexiline.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Silodosin.
PhenytoinThe metabolism of Silodosin can be increased when combined with Phenytoin.
PosaconazoleThe serum concentration of Silodosin can be increased when it is combined with Posaconazole.
PrazosinPrazosin may increase the antihypertensive activities of Silodosin.
PrenylamineSilodosin may increase the hypotensive activities of Prenylamine.
ProgesteroneThe serum concentration of Silodosin can be increased when it is combined with Progesterone.
PropranololThe serum concentration of Silodosin can be increased when it is combined with Propranolol.
QuinidineThe serum concentration of Silodosin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Silodosin can be increased when it is combined with Quinine.
RanolazineThe serum concentration of Silodosin can be increased when it is combined with Ranolazine.
ReserpineThe serum concentration of Silodosin can be increased when it is combined with Reserpine.
RisedronateSilodosin may increase the hypotensive activities of Risedronate.
RitonavirThe serum concentration of Silodosin can be increased when it is combined with Ritonavir.
RolapitantThe serum concentration of Silodosin can be increased when it is combined with Rolapitant.
SaquinavirThe serum concentration of Silodosin can be increased when it is combined with Saquinavir.
SiltuximabThe serum concentration of Silodosin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Silodosin can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Silodosin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Silodosin can be increased when it is combined with Stiripentol.
SunitinibThe serum concentration of Silodosin can be increased when it is combined with Sunitinib.
TacrolimusThe serum concentration of Silodosin can be increased when it is combined with Tacrolimus.
TadalafilTadalafil may increase the hypotensive activities of Silodosin.
TamoxifenThe serum concentration of Silodosin can be increased when it is combined with Tamoxifen.
TelaprevirThe serum concentration of Silodosin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Silodosin can be increased when it is combined with Telithromycin.
TesmilifeneThe serum concentration of Silodosin can be decreased when it is combined with Tesmilifene.
TocilizumabThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Silodosin.
VandetanibThe serum concentration of Silodosin can be increased when it is combined with Vandetanib.
VardenafilVardenafil may increase the hypotensive activities of Silodosin.
VemurafenibThe serum concentration of Silodosin can be increased when it is combined with Vemurafenib.
VerapamilThe serum concentration of Silodosin can be increased when it is combined with Verapamil.
VoriconazoleThe serum concentration of Silodosin can be increased when it is combined with Voriconazole.
Food Interactions
  • The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 − 43% and AUC by 4 − 49%

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
  2. Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr: Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. [PubMed:20071497 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. Functions as a floppase that translocates specifically phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular membrane bilayer into the canaliculi of hepatocytes. Translocation of PC makes the biliary phospholipids available for extraction into the canaliculi ...
Gene Name:
ABCB4
Uniprot ID:
P21439
Molecular Weight:
141521.845 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:17 / Updated on June 24, 2016 01:50